Discovery - University of Dundee - Online Publications

Library & Learning Centre

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

Standard

Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. / Kelly, P.; Paulin, F.; Lamont, D.; Baker, L.; Clearly, S.; Exon, D.; Thompson, A.

In: British Journal of Cancer, Vol. 106, No. 5, 28.02.2012, p. 955-961.

Research output: Contribution to journalArticle

Harvard

Kelly, P, Paulin, F, Lamont, D, Baker, L, Clearly, S, Exon, D & Thompson, A 2012, 'Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer' British Journal of Cancer, vol 106, no. 5, pp. 955-961., 10.1038/bjc.2012.15

APA

Kelly, P., Paulin, F., Lamont, D., Baker, L., Clearly, S., Exon, D., & Thompson, A. (2012). Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. British Journal of Cancer, 106(5), 955-961. 10.1038/bjc.2012.15

Vancouver

Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D et al. Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. British Journal of Cancer. 2012 Feb 28;106(5):955-961. Available from: 10.1038/bjc.2012.15

Author

Kelly, P.; Paulin, F.; Lamont, D.; Baker, L.; Clearly, S.; Exon, D.; Thompson, A. / Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer.

In: British Journal of Cancer, Vol. 106, No. 5, 28.02.2012, p. 955-961.

Research output: Contribution to journalArticle

Bibtex - Download

@article{b1bbe1431f414959802efd9b34364ae7,
title = "Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer",
author = "P. Kelly and F. Paulin and D. Lamont and L. Baker and S. Clearly and D. Exon and A. Thompson",
year = "2012",
doi = "10.1038/bjc.2012.15",
volume = "106",
number = "5",
pages = "955--961",
journal = "British Journal of Cancer",
issn = "0007-0920",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer

A1 - Kelly,P.

A1 - Paulin,F.

A1 - Lamont,D.

A1 - Baker,L.

A1 - Clearly,S.

A1 - Exon,D.

A1 - Thompson,A.

AU - Kelly,P.

AU - Paulin,F.

AU - Lamont,D.

AU - Baker,L.

AU - Clearly,S.

AU - Exon,D.

AU - Thompson,A.

PY - 2012/2/28

Y1 - 2012/2/28

N2 - <p>BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic markers in oesophageal cancer.</p><p>METHODS: Plasma samples collected before and during the treatment of oesophageal cancer and non-cancer controls were analysed by surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectroscopy (MS). Protein peaks were identified by MS in tryptic digests of purified fractions. Associations between peak intensities obtained in the spectra and clinical endpoints (survival, disease-free survival) were tested by univariate (Fisher's exact test) and multivariate analysis (binary logistic regression).</p><p>RESULTS: Plasma protein peaks were identified that differed significantly (P&lt;0.05, ANOVA) between the oesophageal cancer and control groups at baseline. Three peaks, confirmed as apolipoprotein A-I, serum amyloid A and transthyretin, in baseline (pre-treatment) samples were associated by univariate and multivariate analysis with disease-free survival and overall survival.</p><p>CONCLUSION: Plasma proteins can be detected prior to treatment for oesophageal cancer that are associated with outcome and merit testing as prognostic and predictive markers of response to guide chemotherapy in oesophageal cancer. British Journal of Cancer (2012) 106, 955-961. doi:10.1038/bjc.2012.15 www.bjcancer.com Published online 31 January 2012 (C) 2012 Cancer Research UK</p>

AB - <p>BACKGROUND: The incidence of oesophageal adenocarcinoma is increasing worldwide but survival remains poor. Neoadjuvant chemotherapy can improve survival, but prognostic and predictive biomarkers are required. This study built upon preclinical approaches to identify prognostic plasma proteomic markers in oesophageal cancer.</p><p>METHODS: Plasma samples collected before and during the treatment of oesophageal cancer and non-cancer controls were analysed by surface-enhanced laser desorption/ionisation time-of-flight (SELDI-TOF) mass spectroscopy (MS). Protein peaks were identified by MS in tryptic digests of purified fractions. Associations between peak intensities obtained in the spectra and clinical endpoints (survival, disease-free survival) were tested by univariate (Fisher's exact test) and multivariate analysis (binary logistic regression).</p><p>RESULTS: Plasma protein peaks were identified that differed significantly (P&lt;0.05, ANOVA) between the oesophageal cancer and control groups at baseline. Three peaks, confirmed as apolipoprotein A-I, serum amyloid A and transthyretin, in baseline (pre-treatment) samples were associated by univariate and multivariate analysis with disease-free survival and overall survival.</p><p>CONCLUSION: Plasma proteins can be detected prior to treatment for oesophageal cancer that are associated with outcome and merit testing as prognostic and predictive markers of response to guide chemotherapy in oesophageal cancer. British Journal of Cancer (2012) 106, 955-961. doi:10.1038/bjc.2012.15 www.bjcancer.com Published online 31 January 2012 (C) 2012 Cancer Research UK</p>

U2 - 10.1038/bjc.2012.15

DO - 10.1038/bjc.2012.15

M1 - Article

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

VL - 106

SP - 955

EP - 961

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy